回复：合并间质性肺炎的肺癌的药物治疗：证据有限需要适当评估。
Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation.
作者信息
Funke-Chambour Manuela, Kewalramani Namrata, Machahua Carlos, Poletti Venerino, Wells Athol U, Cadranel Jacques
机构信息
Department for BioMedical Research DBMR, Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
出版信息
ERJ Open Res. 2022 Dec 12;8(4). doi: 10.1183/23120541.00469-2022. eCollection 2022 Oct.
Abstract
摘要
https://bit.ly/3DX40fq. （此为网址，无法准确完整翻译其含义，保留原文形式）
相似文献
1
Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation.
ERJ Open Res. 2022 Dec 12;8(4). doi: 10.1183/23120541.00469-2022. eCollection 2022 Oct.
2
Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation.
ERJ Open Res. 2022 Dec 12;8(4). doi: 10.1183/23120541.00337-2022. eCollection 2022 Oct.
3
Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia.
Am J Surg Pathol. 2000 Jan;24(1):19-33. doi: 10.1097/00000478-200001000-00003.
4
Supportive care of patients with fibrosing interstitial lung disease: answering a great clinical need.
Breathe (Sheff). 2020 Sep;16(3):200066. doi: 10.1183/20734735.0066-2020.
5
Managing Lung Cancer with Comorbid Interstitial Pneumonia.
Intern Med. 2020 Jan 15;59(2):163-167. doi: 10.2169/internalmedicine.3481-19. Epub 2019 Sep 18.
6
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5.
7
Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases.
Hum Pathol. 2008 Sep;39(9):1275-94. doi: 10.1016/j.humpath.2008.05.009.
8
Distinctive characteristics and prognostic significance of interstitial pneumonia with autoimmune features in patients with chronic fibrosing interstitial pneumonia.
Respir Med. 2018 Apr;137:167-175. doi: 10.1016/j.rmed.2018.02.024. Epub 2018 Mar 1.
9
Erratum to "Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases" [Hum Pathol 39 (2008) 1275-1294].
Hum Pathol. 2008 Nov;39(11):1562-81. doi: 10.1016/j.humpath.2008.09.001.
10
Spectrum of fibrosing diffuse parenchymal lung disease.
Mt Sinai J Med. 2009 Feb;76(1):2-23. doi: 10.1002/msj.20087.
本文引用的文献
1
Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study.
Oncologist. 2022 Sep 2;27(9):720-e702. doi: 10.1093/oncolo/oyac118.
2
Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges.
ERJ Open Res. 2022 Jun 20;8(2). doi: 10.1183/23120541.00115-2022. eCollection 2022 Apr.
3
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Eur Respir J. 2022 Dec 15;60(6). doi: 10.1183/13993003.00380-2022. Print 2022 Dec.
4
Different treatment efficacies and side effects of cytotoxic chemotherapy.
J Thorac Dis. 2020 Jul;12(7):3785-3795. doi: 10.21037/jtd.2019.08.63.
5
Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan.
ERJ Open Res. 2020 May 26;6(2). doi: 10.1183/23120541.00184-2019. eCollection 2020 Apr.
6
S-1 as an option for second-line treatment of NSCLC. Is the 'East Side Story' applicable in the West?
Ann Oncol. 2017 Nov 1;28(11):2627-2629. doi: 10.1093/annonc/mdx519.
7
A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
Lung Cancer. 2017 Sep;111:1-5. doi: 10.1016/j.lungcan.2017.06.008. Epub 2017 Jun 17.
8
Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1.
Respir Investig. 2017 Mar;55(2):145-152. doi: 10.1016/j.resinv.2016.10.008. Epub 2016 Dec 10.
9
Current Development of Anti-Cancer Drug S-1.
J Clin Diagn Res. 2016 Nov;10(11):XE01-XE05. doi: 10.7860/JCDR/2016/19345.8776. Epub 2016 Nov 1.
10
Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival.
J Cancer Res Clin Oncol. 2016 Aug;142(8):1855-65. doi: 10.1007/s00432-016-2199-z. Epub 2016 Jun 27.
Zotero 插件